Prognostic significance of neutrophil to lymphocyte ratio in pancreatic cancer: A meta-analysis

Table 1 Baseline characteristics of the included studies

Ref.	Country	Treatment	NLR cutoff, n	HR estimation	Outcome measured	Sample/high NLR, n	HR(95%CI)	Study quality (points)
Martin et al[21]	Austria	Chemo	5	HR	OS	124/64	1.6 (1.07-2.4)	8/9
Wang et al[22]	China	Mix	5	HR	OS	177/32	2.537 (1.313-4.902)	6/9
Xue et al[23]	Japan	Chemo	5	HR	OS	252/40	1.92 (1.27-2.9)	6/9
Sugiura et al[24]	Japan	Mix	4	Survival curve	OS	83/36	6.4 (2.85-14.34)	8/9
Bhatti et al[25]	United Kingdom	Sur	4	HR	OS	84/13	1.2 (1.01-1.449)	7/9
Aliustaoglu et al[26]	Japan	Mix	5	Survival curve	OS	65/9	5.42 (2.96-9.91)	7/9
Teo et al[27]	Ireland	Chemo	3	HR	OS	85/58	2.93 (1.59-5.64)	5/9
An et al[28]	China	Chemo	5	HR	OS	89/16	4.489 (1.372-14.692)	7/9
Szkandera et al[29]	Austria	Mix	2.3	HR	CCS	474/271	1.24 (1.01-1.51)	7/9
Stotz et al[30]	Austria	Mix	5	HR	CCS	261/79	2.532 (1.64-3.91)	6/9
Stotz et al[30]	Austria	Sur	5	HR	CCS	110/37	1.611 (1.024-2.534)	7/9

Studies evaluated mixed treatment (Mix), chemotherapy (Chemo), or surgical resection (Sur). Study quality is listed using the results of the Newcastle-Ottawa questionnaire. HR: Hazard ratio; OS: Overall survival; CSS: Cancer specific survival; NLR: Neutrophil to lymphocyte ratio.